The puzzle of multiple sclerosis: gray matter finds its place

References

• Peterson JW, Bö L, Mörk S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurology50(3), 389–400 (2001).
   PubMed Web of Science ®Google Scholar
• Vercellino M, Masera S, Lorenzatti M et al. Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J. Neuropathol. Exp. Neurol.68(5), 489–502 (2009).
   PubMed Web of Science ®Google Scholar
• Kutzelnigg A, Lucchinetti CF, Stadelmann C et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain128(11), 2705–2712 (2005).
   PubMed Web of Science ®Google Scholar
• Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. Cortical lesions in multiple sclerosis. Brain122(1), 17–26 (2001).
   Google Scholar
• Geurts JJ, Barkhof F. Grey matter pathology in multiple sclerosis. Lancet Neurol.7(9), 841–851 (2008).
   PubMed Web of Science ®Google Scholar
• Geurts JJ, Pouwels PJ, Uitdehaag BM, Polman CH, Barkhof F, Castelijns JA. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology236(1), 254–260 (2005).
   PubMed Web of Science ®Google Scholar
• Sailer M, Fischi B, Salat D et al. Focal thinning of the cerebral cortex in multiple sclerosis. Brain126(8), 1734–1744 (2003).
   PubMed Web of Science ®Google Scholar
• Dalton CM, Chard DT, Davies GR et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain127(5), 1101–1107 (2004).
   PubMed Web of Science ®Google Scholar
• Sastre-Garriga J, Ingle GT, Chard DT, Ramió-Torrentà L, Miller DH, Thompson AJ. Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis. Neuroimage22(1), 353–359 (2004).
   PubMed Web of Science ®Google Scholar
• Ramasamy DP, Benedict R, Cox J et al. Extent of cerebellum, subcortical and cortical atrophy in patients with MS. A case–control study. J. Neurol. Sci.282, 47–54 (2009).
   PubMedGoogle Scholar
• Calabrese M, Gallo P. Magnetic resonance evidence of cortical onset of multiple sclerosis. Mult. Scler.15(8), 933–941 (2009).
   PubMed Web of Science ®Google Scholar
• Popescu BF, Bunyan RF, Parisi JE, Ransohoff RM, Lucchinetti CF. A case of multiple sclerosis presenting with inflammatory cortical demyelination. Neurology76(20), 1705–1710 (2011).
   PubMedGoogle Scholar
• Barkhof F. The clinico–radiological paradox in multiple sclerosis revisited. Curr. Opin. Neurol.15(3), 239–245 (2002).
   PubMed Web of Science ®Google Scholar
• Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, ThompsonAJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Eng. J. Med.346(3), 158–164 (2002).
   PubMed Web of Science ®Google Scholar
• Fisniku LK, Chard DT, Jackson JS et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann. Neurol.64(3), 247–254 (2008).
   PubMed Web of Science ®Google Scholar
• Roosendaal SD, Bendfeldt K, Vrenken H et al. Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult. Scler.17(9), 1098–1106 (2011).
   PubMed Web of Science ®Google Scholar
• Jasperse B, Valsasina P, Neacsu V et al. Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually edited SIENA and SIENAX. J. Magn. Reson. Imaging26(4), 881–885 (2007).
   PubMedGoogle Scholar
• De Stefano N, Matthews PM, Filippi M et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology60(7), 1157–1162 (2003).
   PubMed Web of Science ®Google Scholar
• Calabrese M, Rocca MA, Atzori M et al. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis. Ann. Neurol.67(3), 376–383 (2010).
   PubMed Web of Science ®Google Scholar
• Roosendaal SD, Moraal B, Pouwels PJ et al. Accumulation of cortical lesions in MS: relation with cognitive impairment. Mult. Scler.15(6), 708–714 (2009).
   PubMed Web of Science ®Google Scholar
• Calabrese M, Agosta F, Rinaldi F et al. Cortical lesions and atrophy associated with cognitive impairment in relapsingremitting multiple sclerosis. Arch. Neurol.66(9), 1144–1150 (2009).
   PubMedGoogle Scholar
• Rovaris M, Judica E, Gallo A et al. Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. Brain129(10), 2628–2634 (2006).
   PubMed Web of Science ®Google Scholar
• Amato MP, Portaccio E, Goretti B et al. Cognitive impairment in early stages of multiple sclerosis. Neurol. Sci.31, S211–S214 (2010).
   PubMed Web of Science ®Google Scholar
• Calabrese M, Rinaldi F, Mattisi I et al. Widespread cortical thinning characterizes patients with MS with mild cognitive impairment. Neurology74(4), 321–328 (2010)
   PubMed Web of Science ®Google Scholar
• Filippi M, Rocca MA, Calabrese M et al. Intracortical lesions: relevance for new MRI diagnostic criteria for multiple sclerosis. Neurology75(22), 1988–1994 (2010).
   PubMed Web of Science ®Google Scholar
• Calabrese M, Rinaldi F, Mattisi I et al. The predictive value of gray matter atrophy in clinically isolated syndromes. Neurology77(3), 257–263 (2011).
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 revision to the McDonald criteria. Ann. Neurol.69(2), 292–302 (2011).
   PubMed Web of Science ®Google Scholar
• Filippi M, Rovaris M, Inglese M et al Interferon β-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet364(9444), 1489–1496 (2004).
   PubMed Web of Science ®Google Scholar
• Calabrese M, Bernardi V, Atzori M et al. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple. Mult. Scler. DOI: 10.1177/1352458510394702 (2011) (Epub ahead of print).
   Google Scholar
• Bendfeldt K, Egger H, Nichols TE et al. Effect of immunomodulatory medication on regional gray matter loss in relapsing–remitting multiple sclerosis – a longitudinal MRI study. Brain Res.14(1325), 174–182 (2010).
   Google Scholar
• Derfuss T, Parikh K, Velhin S et al. Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc. Natl Acad. Sci. USA19(106), 8302–8307 (2009).
   Google Scholar